ImmuPharma plc (LON:IMM – Get Free Report) shares fell 15.6% during trading on Thursday . The company traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.98 ($0.06). 68,204,375 shares changed hands during mid-day trading, an increase of 164% from the average session volume of 25,820,418 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Trading Down 9.7 %
The business has a 50 day simple moving average of GBX 1.98 and a two-hundred day simple moving average of GBX 1.80. The stock has a market cap of £18.39 million, a price-to-earnings ratio of -441.60 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Profitably Trade Stocks at 52-Week Highs
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Steel Stocks Soaring After Tariff Announcements
- Dividend Capture Strategy: What You Need to Know
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
